Pituitary lesions often present benign adenomas that are either secreting or non-secreting. Their size, type and associated symptoms determine the modality of treatment.
If a patient with recent imaging evidence of a pituitary lesion presents acutely with progressive visual field defect, evidence of haemorrhage on imaging or focal cranial nerve palsies, please refer urgently to the on-call via Refer-a-Patient, as these patients may require surgical decompression.
If there is evidence of a new and incidental pituitary lesion, without acutely worsening neurological symptoms, please refer to the local endocrinology service. They will discuss the case with our services via the pituitary MDT if appropriate.
For questions regarding known pituitary tumours where the patient is already known to endocrinology, please refer via the Pituitary MDT - use the link for the skull-base MDT and then select the pituitary MDT in the referral form.
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.